Lisdexamfetamine
Vyvanse (lisdexamfetamine) is a small molecule pharmaceutical. Lisdexamfetamine was first approved as Vyvanse on 2007-02-23. It is used to treat attention deficit disorder with hyperactivity and binge drinking in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Vyvanse
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vyvanse | New Drug Application | 2019-10-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| attention deficit disorder with hyperactivity | EFO_0003888 | D001289 | F90 |
| binge drinking | — | D063425 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Lisdexamfetamine Dimesylate, Vyvanse, Takeda Pharms Usa | |||
| 7105486 | 2023-02-24 | U-727, U-842 | |
| 7223735 | 2023-02-24 | DP | |
| 7655630 | 2023-02-24 | DP | |
| 7659253 | 2023-02-24 | DS, DP | U-727 |
| 7659254 | 2023-02-24 | U-727, U-1034 | |
| 7662787 | 2023-02-24 | DP | |
| 7662788 | 2023-02-24 | U-727 | |
| 7671030 | 2023-02-24 | DP | U-727 |
| 7671031 | 2023-02-24 | U-727 | |
| 7674774 | 2023-02-24 | DP | U-727, U-842 |
| 7678770 | 2023-02-24 | U-727, U-842 | |
| 7678771 | 2023-02-24 | DP | U-727, U-842 |
| 7687466 | 2023-02-24 | DP | |
| 7687467 | 2023-02-24 | DP | U-727, U-842 |
| 7700561 | 2023-02-24 | DP | |
| 7713936 | 2023-02-24 | U-727 | |
| 7718619 | 2023-02-24 | DP | U-727, U-842 |
| 7723305 | 2023-02-24 | DP | U-727, U-842 |
HCPCS
No data
Clinical
Clinical Trials
131 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | 2 | 12 | 10 | 1 | 1 | 19 | |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 6 | 2 | 4 | 12 |
| Gram-positive bacterial infections | D016908 | — | 1 | 3 | 1 | 2 | 7 | ||
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | — | 2 | 2 | 1 | 5 |
| Soft tissue infections | D018461 | — | — | 3 | 1 | — | 4 | ||
| Methicillin-resistant staphylococcus aureus | D055624 | — | — | — | 3 | 1 | 4 | ||
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | 2 | 1 | — | 3 |
| Endocarditis | D004696 | EFO_0000465 | I33 | — | — | — | 3 | — | 3 |
| Critical illness | D016638 | — | — | — | 1 | 1 | 2 | ||
| Catheter-related infections | D055499 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial infections | D001424 | A49 | 2 | 4 | 9 | — | — | 15 | |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 9 | 8 | — | — | 13 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 2 | 4 | 4 | — | 2 | 10 |
| Extensively drug-resistant tuberculosis | D054908 | 2 | 7 | 6 | — | — | 9 | ||
| Bacterial skin diseases | D017192 | — | 4 | 1 | — | 1 | 6 | ||
| Infectious skin diseases | D012874 | — | 2 | 2 | — | 1 | 5 | ||
| Abscess | D000038 | EFO_0003030 | — | 1 | 2 | — | 1 | 4 | |
| Healthcare-associated pneumonia | D000077299 | — | — | 1 | — | 2 | 3 | ||
| Staphylococcal infections | D013203 | A49.01 | — | — | 1 | — | 2 | 3 | |
| Surgical wound infection | D013530 | — | — | 3 | — | — | 3 |
Show 12 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Meningeal tuberculosis | D014390 | A17.0 | — | 3 | — | — | 1 | 4 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | 1 | 2 |
| Neoplasms | D009369 | C80 | — | 1 | — | — | — | 1 | |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | — | — | — | 1 |
| Staphylococcal skin infections | D013207 | EFO_1001849 | L00 | — | 1 | — | — | — | 1 |
| Streptococcal infections | D013290 | EFO_1001476 | — | 1 | — | — | — | 1 | |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial meningitis | D016920 | EFO_1000831 | G00 | — | — | — | — | 1 | 1 |
| Cerebral hemorrhage | D002543 | — | — | — | — | 1 | 1 | ||
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | — | — | 1 | 1 |
| Drug monitoring | D016903 | — | — | — | — | 1 | 1 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | — | 1 | 1 |
| Sepsis | D018805 | A41.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LISDEXAMFETAMINE |
| INN | lisdexamfetamine |
| Description | Lisdexamfetamine is an amino acid amide. |
| Classification | Small molecule |
| Drug class | amfetamine derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN |
Identifiers
| PDB | — |
| CAS-ID | 608137-32-2 |
| RxCUI | 700810 |
| ChEMBL ID | CHEMBL1201222 |
| ChEBI ID | — |
| PubChem CID | 11597698 |
| DrugBank | DB01255 |
| UNII ID | H645GUL8KJ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Vyvanse - Takeda
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Vyvanse - Shire
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,600 documents
View more details
Safety
Black-box Warning
Black-box warning for: Vyvanse
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
17,105 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more